Aurobindo Pharma Limited

Greenhouse gas emissions & sustainability report data

📊 Latest report period: 2022-04 to 2023-03🗂️ Report periods on file: 2022-04 to 2023-03, 2021-22, 2020-2021, 2019-20, 2018-19

In its 2022-04 to 2023-03 reporting, Aurobindo Pharma Limited disclosed greenhouse gas emissions of 941.5K tCO2e/year. By scope: Scope 1: 447.2K tCO2e/year; Scope 2: 494.3K tCO2e/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.

💨
GHG Emissions
941.5K tCO2e/year
2022-04 to 2023-03
⚡
Renewable Energy
12%
of total energy
💧
Water Usage
3.7K ML/year
2022-04 to 2023-03
♻️
Waste
49.4K tons/year
2022-04 to 2023-03
⚙️
Energy Use
6.9M GJ/year
2022-04 to 2023-03

📊 Emissions by Scope (2022-04 to 2023-03)

ScopeWhat it coversReported value
Scope 1Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions).447.2K tCO2e/year
Scope 2Indirect emissions from purchased electricity, steam, heat and cooling.494.3K tCO2e/year

New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.

📈 Emissions by Report Period

Report periodHeadline emissions figure reported
2022-04 to 2023-03941.5K tCO2e/year
2021-2297.2K tCO2e
2020-2021903.4K tCO2e/year

Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.

✅ Reported Environmental Achievements

🎯 Climate & Sustainability Targets

🔜 Short-term

  • Assess 100% of key starting material suppliers in India by 2025

📅 Medium-term

  • Achieve 20% renewable energy share (Power-to-Power) by 2025
  • Achieve 12.75% women in the workforce by 2025
  • Achieve 25 hours of learning per employee by 2025
  • Achieve zero reportable incidents across operations by 2025

🌱 ESG Focus Areas

Climate ChangeWater ManagementWaste ManagementRenewable EnergyDiversity & InclusionEmployee Well-beingCorporate Social ResponsibilitySupply Chain SustainabilityRegulatory ComplianceHuman Rights

⚠️ Challenges & Risks +

  • Challenging macro environment and intense industry competition
  • Price erosion in US generics business and high input price inflation
  • Supply chain disruptions
  • Water scarcity in some locations
  • Antimicrobial resistance (AMR)
  • Regulatory compliance in various markets
  • Competition risks
  • Pricing pressures
  • Market risks (concentration in US and Europe)
  • Patent protection risks

📋 Report Information

Reporting Period: 2022-04 to 2023-03
Frameworks: Integrated Reporting (IR) Framework, Science Based Targets initiative (SBTi), Pharmaceutical Supply Chain Initiative (PSCI), AMR Industry Alliance